Characterising the prognostic potential of HLA-DR during colorectal cancer development
2020 · Cancer Immunology Immunotherapy · 35 citations
https://doi.org/10.1007/s00262-020-02571-2
P
Petra Martin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
70
Papers
870
Citations
16
h-index
19
i10-index
Petra Martin is an academic researcher from Midland Regional Hospital at Tullamore. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Colorectal Cancer Treatments and Studies & Cancer Genomics and Diagnostics. The author has an h-index of 16, co-authored 60 publications.
Papers by this author
worksPredicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
2014 · BMC Cancer · 33 citations
https://doi.org/10.1186/1471-2407-14-887
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
2016 · British Journal of Cancer · 18 citations
https://doi.org/10.1038/bjc.2016.22
EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings
2024 · Value in Health · 0 citations
https://doi.org/10.1016/j.jval.2024.03.391
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat